Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
08 avr. 2024 08h30 HE
|
Coherus BioSciences, Inc.
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion ––...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
13 mars 2024 16h01 HE
|
Coherus BioSciences, Inc.
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net...
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
05 mars 2024 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be...
Coherus Completes Divestiture of Ophthalmology Franchise
04 mars 2024 01h00 HE
|
Coherus BioSciences, Inc.
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) --...
Coherus BioSciences Announces New Employment Inducement Grants
23 févr. 2024 17h33 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation...
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
21 févr. 2024 08h30 HE
|
Coherus BioSciences, Inc.
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
05 févr. 2024 08h00 HE
|
Coherus BioSciences, Inc.
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be...
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
22 janv. 2024 01h15 HE
|
Coherus BioSciences, Inc.
– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus...
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
18 janv. 2024 16h05 HE
|
Coherus BioSciences, Inc.
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel...
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 09h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P....